Literature DB >> 22714538

Oncolytic viruses in the treatment of cancer: a review of current strategies.

Md Zeyaullah1, Mohan Patro, Irfan Ahmad, Kawthar Ibraheem, P Sultan, M Nehal, Arif Ali.   

Abstract

Oncolytic viruses are live, replication-competent viruses that replicate selectively in tumor cells leading to the destruction of the tumor cells. Tumor-selective replicating viruses offer appealing advantages over conventional cancer therapy and are promising a new approach for the treatment of human cancer. The development of virotherapeutics is based on several strategies. Virotherapy is not a new concept, but recent technical advances in the genetic modification of oncolytic viruses have improved their tumor specificity, leading to the development of new weapons for the war against cancer. Clinical trials with oncolytic viruses demonstrate the safety and feasibility of an effective virotherapeutic approach. Strategies to overcome potential obstacles and challenges to virotherapy are currently being explored. Systemic administrations of oncolytic viruses will successfully extend novel treatment against a range of tumors. Combination therapy has shown some encouraging antitumor responses by eliciting strong immunity against established cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22714538     DOI: 10.1007/s12253-012-9548-2

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   2.874


  143 in total

1.  China approves world's first oncolytic virus therapy for cancer treatment.

Authors:  Ken Garber
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

2.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

Authors:  J A McCart; J M Ward; J Lee; Y Hu; H R Alexander; S K Libutti; B Moss; D L Bartlett
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.

Authors:  Dawn E Post; Erwin G Van Meir
Journal:  Oncogene       Date:  2003-04-10       Impact factor: 9.867

4.  Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.

Authors:  Simon Leveille; Marie-Line Goulet; Brian D Lichty; John Hiscott
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

5.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

Authors:  Andrew L Pecora; Naiyer Rizvi; Gary I Cohen; Neal J Meropol; Daniel Sterman; John L Marshall; Stuart Goldberg; Peter Gross; James D O'Neil; William S Groene; M Scot Roberts; Harvey Rabin; Michael K Bamat; Robert M Lorence
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

6.  Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.

Authors:  R M MacKie; B Stewart; S M Brown
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

7.  Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Authors:  R Rampling; G Cruickshank; V Papanastassiou; J Nicoll; D Hadley; D Brennan; R Petty; A MacLean; J Harland; E McKie; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

8.  The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

Authors:  D C Yu; Y Chen; M Seng; J Dilley; D R Henderson
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

Review 9.  Antineoplastic activity of parvoviruses.

Authors:  J Rommelaere; J J Cornelis
Journal:  J Virol Methods       Date:  1991-08       Impact factor: 2.014

10.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

View more
  27 in total

Review 1.  Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics.

Authors:  Joseph Yoo; C Andrew Kistler; Linda Yan; Andrew Dargan; Ali A Siddiqui
Journal:  J Gastrointest Oncol       Date:  2016-12

2.  Inactivated Sendai virus strain Tianjin induces apoptosis in breast cancer MCF-7 cells by promoting caspase activation and Fas/FasL expression.

Authors:  Li-Ying Shi; Zhe Han; Xiao-Xia Li; Mei Li; Han Han; Jun Chen; Sitao Zang
Journal:  Cancer Biother Radiopharm       Date:  2014-12-17       Impact factor: 3.099

Review 3.  Reovirus: a targeted therapeutic--progress and potential.

Authors:  Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

Review 4.  Synthetic immunosurveillance systems: nanodevices to monitor physiological events.

Authors:  Yvon L Woappi; Rahul Jangiti; Om V Singh
Journal:  Biosens Bioelectron       Date:  2014-05-10       Impact factor: 10.618

5.  Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Authors:  Theresa Falls; Dominic Guy Roy; John Cameron Bell; Marie-Claude Bourgeois-Daigneault
Journal:  ILAR J       Date:  2016

Review 6.  Oncolytic virotherapy: the questions and the promise.

Authors:  Laure Aurelian
Journal:  Oncolytic Virother       Date:  2013-05-31

7.  Tricistronic expression of MOAP-1, Bax and RASSF1A in cancer cells enhances chemo-sensitization that requires BH3L domain of MOAP-1.

Authors:  Yong Hoi Lee; Siew Wai Pang; Esther Revai Lechtich; Khalid Shah; Samson Eugin Simon; Suriyan Ponnusamy; Ramesh Narayanan; Chit Laa Poh; Kuan Onn Tan
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-06       Impact factor: 4.553

8.  Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.

Authors:  C Batenchuk; F Le Boeuf; L Stubbert; T Falls; H L Atkins; J C Bell; D P Conrad
Journal:  Blood Cancer J       Date:  2013-07-12       Impact factor: 11.037

9.  Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis.

Authors:  Amanda Sierra; Oihane Abiega; Anahita Shahraz; Harald Neumann
Journal:  Front Cell Neurosci       Date:  2013-01-30       Impact factor: 5.505

10.  Construction of HCC-targeting artificial miRNAs using natural miRNA precursors.

Authors:  Xiaoming Huang; Zhenyu Jia
Journal:  Exp Ther Med       Date:  2013-05-14       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.